Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

BVF Partners

Investor type Hedge Fund


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 60
Average round size
The average size of a deal this fund participated in
Portfolio companies 52
Rounds per year 2.00
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 28
Key employees Soon

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Pharmaceutical
  • Life Science

The leading representative office of defined Corporate Investor is situated in the San Francisco. The venture was found in North America in United States.

The usual cause for the fund is to invest in rounds with 5 partakers. Despite the BVF Partners, startups are often financed by Purdue Pharma, Versant Ventures, MPM Capital. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Wellington Management, Surveyor Capital.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Repare Therapeutics. For fund there is no match between the location of its establishment and the land of its numerous investments - Canada. Among the most successful fund investment fields, there are Health Care, Pharmaceutical.

The important activity for fund was in 2019. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is generally included in 2-6 deals every year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of BVF Partners:
Typical Co-investors
BVF Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after BVF Partners:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
1to4 Foundation -
Aoou Wangluo Keji China, Shanghai
AXON Connected Earlysville, United States, Virginia
Barclays Investment Bank Atlanta, Georgia, United States
Caspark Beijing, China, Haidian
Christavest -
Derbaix Ventures Community of Madrid, Madrid, Spain
Gollust Management -
Grupo Pegasus -
GU Equity Partners -
Hike Delhi, India, New Delhi
Pamica -
Pioneer -
SPARK VCT England, London, United Kingdom
Tennenbaum Capital Partners California, Santa Monica, United States
Whales Capital China, Shanghai
White Owl Capital Partners New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Palvella Therapeutics

Health Care
Life Science
$37M05 Jan 2023 Radnor Township, Pennsylvania, United States

Alpha9 Theranostics

Product Research
$75M14 Dec 2022 Vancouver, British Columbia, Canada

NLS Pharma

Health Care
$10M07 Dec 2022 Stans, Nidwalden, Switzerland


Life Science
$60M10 Oct 2022 San Diego, California, United States


$75M04 Oct 2022 New York, New York, United States


Health Care
$150M19 Sep 2022 California, United States

Autobahn Therapeutics

Health Care
Life Science
$32M08 Sep 2022 San Diego, California, United States

ESSA Pharma

$13M08 Jul 2022 Vancouver, British Columbia, Canada

Dren Bio

Health Care
Life Science
$65M14 Jun 2022 California, United States
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BVF Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: